Clinical Trial Update: A Study of Gefapixant (AF-219/MK-7264) in Participants With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016) [Phase 2]

View source ↗

Summary

Phase 2 study of Gefapixant (MK-7264) in idiopathic pulmonary fibrosis patients with persistent cough has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cough
• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• Gefapixant (gefapixant)

Snippet

Sponsor: Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Idiopathic Pulmonary Fibrosis, Cough | Phase 2 | Status: COMPLETED | Results posted: 2021-05-26